

Ask the Expert: Clinical Investigators Provide Perspectives on the Management of Renal Cell Carcinoma — In Partnership with Project Echo® and Florida Cancer Specialists

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What were the pivotal findings of the Phase III CARMINA trial comparing up-front cytoreductive nephrectomy followed by sunitinib to sunitinib alone for patients with intermediate- or poor-risk metastatic renal cell carcinoma (RCC)?**
 - Nephrectomy followed by sunitinib was superior to sunitinib alone
 - Sunitinib alone was not inferior to nephrectomy followed by sunitinib
- 2. Which of the following drugs is being evaluated in combination with cabozantinib in the Phase III CONTACT-03 trial for patients with advanced RCC who have previously received immunotherapy?**
 - Pembrolizumab
 - Nivolumab
 - Atezolizumab
- 3. Which of the following drug types best describes cabozantinib?**
 - Tyrosine kinase inhibitor
 - mTOR inhibitor
 - Immunotherapy
 - Antibody-drug conjugate
- 4. On the basis of results from the Phase III CheckMate 214 trial, the combination of nivolumab and ipilimumab received FDA approval for patients with intermediate- or poor-risk advanced RCC in which line of treatment?**
 - First line
 - Second line after sunitinib
 - Third line or later